Mesoblast Stock Quote MESO - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

6.28

Bid

6.28

Ask

6.29

Volume

157,157

6.04 Day's Range 6.36

0.00 52 Week Range 0.00

Market Cap

756.706M

Previous Close

6.15

Open

6.04

Last Trade

6.28

Last Trade Time

12:49:01

Financial Volume

$ 967,215

VWAP

6.1544

Average Volume (3m)

Shares Outstanding

813,662,000

Dividend Yield

PE Ratio

-9.24

Earnings Per Share (EPS)

-0.1

Revenue

19.85M

Net Profit

-81.89M

Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-... Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.mesoblast.com

Headquarters

Melbourne, Victoria, Aus

Founded

1970

Mesoblast Limited is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker MESO. The last closing price for Mesoblast was $6.15. Over the last year, Mesoblast shares have traded in a share price range of $ 0.00 to $ 0.00.

Mesoblast currently has 813,662,000 shares outstanding. The market capitalization of Mesoblast is $756.71 million. Mesoblast has a price to earnings ratio (PE ratio) of -9.24.

FDA Commentary Sends Biotech Soaring During Premarket Hours

A biotech stock that has seen some pretty wild price swings as of late is turning heads so far during Tuesday’s premarket after the company was notified by the U.S. FDA that To read the full...

United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA has...

Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer

NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has received...

United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)

NEW YORK, March 10, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that U.S. FDA...

Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an operational...

Mesoblast Financial Results and Corporate Update Webcast

NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss...

United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease

NEW YORK, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United...

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023

NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BDRXBiodexa Pharmaceuticals PLC	$ 1.175 (62.11%)	60.73M
NUZENuZee Inc	$ 1.89 (54.92%)	1.02M
NIVFNewGenIvf Group Ltd	$ 1.85 (42.31%)	52.82M
PEGYPineapple Energy Inc	$ 0.0731 (40.85%)	274.63M
ULHUniversal Logistics Holdings Inc	$ 45.69 (38.92%)	345.14k
ISUNiSun Inc	$ 0.1517 (-95.60%)	8.26M
MFImF International Ltd	$ 2.5001 (-76.05%)	14.09M
NWGLNature Wood Group Ltd	$ 5.00 (-70.33%)	1.54M
ICLKiClick Interactive Asia Group Ltd	$ 1.325 (-47.63%)	609.81k
NUWENewellis Inc	$ 0.1735 (-39.97%)	16.14M
PEGYPineapple Energy Inc	$ 0.0731 (40.85%)	274.63M
SQQQProShares UltraPro Short QQQ	$ 11.385 (-5.13%)	92.27M
INTCIntel Corporation	$ 31.69 (-9.74%)	76.54M
TSLATesla Inc	$ 171.4995 (0.78%)	61.07M
BDRXBiodexa Pharmaceuticals PLC	$ 1.175 (62.11%)	60.73M